Guru Ownership Trend
Guru Analysis for TG Therapeutics, Inc. (TGTX)
TG Therapeutics, Inc. (TGTX), a key player in the Healthcare sector, continues to attract institutional attention.
As of Q3 2026, a total of 7 Super Investors (Gurus) hold positions in the company, with a combined stake valued at approximately $127.7 M.
Top institutional holders include Ray Dalio and Steven Cohen.
Institutional sentiment is currently Bullish. This is evidenced by a $547,500.39 net inflow during the quarter.
Recent activity highlights Larry Robbins who opened a new position. Conversely, Renaissance Technologies (RenTech) reduced exposure by 33.9%.
Key Holders
Top 5 by Value
Top 5 by Conviction
Recent Activity Breakdown (Q3 2026)
Guru Consensus (Q3 2026)
FAQs for TG Therapeutics, Inc. (TGTX)
Major holders include Ray Dalio ($32.72 M), Steven Cohen ($25.17 M), Renaissance Technologies (RenTech) ($25.05 M). According to the latest reported data, 7 tracked investment managers collectively hold approximately 2.02 M shares.
According to the latest 13F reporting period, sentiment appears Bullish (Net Buying). There was a net inflow of $547,500.39, with 3 managers increasing positions and 4 managers reducing holdings.
During the most recent reporting period, 3 managers trimmed their positions, while 1 fully exited TGTX. The total reported sell value was $18.85 M.
Yes, 1 managers opened new positions in TGTX, and 2 increased their existing holdings. The total reported buy value was $19.4 M.